Email Us
Call Us
Chimeric antigen receptor natural killer cell therapy applies the targeting principle of CAR-T to a different effector cell, and the differences between the two are the reason the approach exists. Natural killer cells kill through both antigen-directed and innate mechanisms, so a CAR-NK product retains activity against target-negative tumor cells that a CAR-T product would miss. They also carry a different toxicity profile, with allogeneic products not producing graft-versus-host disease in the way donor T cells do, which supports an off-the-shelf rather than patient-specific manufacturing model.
Altogen Labs conducts preclinical evaluation of CAR-NK products across disseminated and solid tumor models, with antitumor activity, persistence, and effector phenotype measured together. To discuss a study design, request a quote.
Model requirements specific to NK products
NK biology imposes a constraint that CAR-T work does not. Human natural killer cells require interleukin 15 and related cytokine support for survival and expansion, and murine cytokines do not substitute adequately. In a conventional immunodeficient host without that support, transferred NK cells decline rapidly, and a study measuring persistence in such a host will report poor persistence as a property of the product when it is a property of the model.
Study design therefore addresses cytokine support explicitly, whether through host selection, supplementation, or a product engineered for cytokine independence. This is settled at design stage rather than discovered when the persistence data arrive.
Dual mechanism assessment
Because CAR-NK products act through both the engineered receptor and innate recognition, study design frequently needs to separate the two. Including target-negative tumor cells or a target-negative model arm establishes how much activity derives from the chimeric receptor and how much from innate mechanisms, which matters for predicting behavior against heterogeneous tumors and against antigen-loss escape.
Antigen density in the model is a related consideration, since receptor-dependent killing has a density threshold and a model expressing target far above clinical levels will overstate activity.
Endpoints
Disseminated models established with reporter-tagged lines are followed by longitudinal imaging. Solid tumor models are followed by volume or imaging by site. Persistence and phenotype of the transferred product are quantified by flow cytometry in blood and tissue, with activation and exhaustion markers included where relevant. Cytokine analysis characterizes the release profile, which differs from that of T-cell products.
Applied examples
Antigen-independent activity. A CAR-NK product is evaluated against matched target-positive and target-negative tumor models, quantifying the contribution of innate killing to overall activity.
Persistence with cytokine support. The same product is assessed in hosts with and without cytokine support, establishing the extent to which observed persistence depends on the model rather than the construct.
Comparison against a T-cell product. A CAR-NK and a CAR-T product directed at the same antigen are evaluated in matched models, with tumor control, persistence, and cytokine release compared under identical conditions.
Interpretive limits and service boundary
Human NK biology is incompletely reproduced in murine hosts, and persistence, trafficking, and cytokine responses observed preclinically should be interpreted against that limitation rather than extrapolated directly. Where the question concerns durability, host cytokine support is the dominant variable and is reported alongside the result.
Altogen Labs evaluates cell therapy products supplied by the client. Manufacture of CAR-NK or other cell therapy products is not offered. All procedures are conducted under active IACUC protocols. GLP standards are applied where a study is formally designated as GLP.
Send product details, target antigen, and cytokine support requirements, or request a quote.